<SEC-DOCUMENT>0001213900-22-011983.txt : 20220314
<SEC-HEADER>0001213900-22-011983.hdr.sgml : 20220314
<ACCEPTANCE-DATETIME>20220314071359
ACCESSION NUMBER:		0001213900-22-011983
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220314
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220314
DATE AS OF CHANGE:		20220314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEKTAR THERAPEUTICS
		CENTRAL INDEX KEY:			0000906709
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943134940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24006
		FILM NUMBER:		22735062

	BUSINESS ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		4154825300

	MAIL ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS INC
		DATE OF NAME CHANGE:	19980723

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS
		DATE OF NAME CHANGE:	19940303
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea156805-8k_nektarther.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:NKTR="http://nektar.com/20220314">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_NKTR_nektar.com_20220314 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20220314_20220314 -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0000906709 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-03-14to2022-03-14" name="dei:EntityCentralIndexKey">0000906709</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-03-14to2022-03-14" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="nktr-20220314.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-03-14to2022-03-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-14</xbrli:startDate>
        <xbrli:endDate>2022-03-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_903_edei--DocumentType_c20220314__20220314_zcH0hqFwlhdk"><ix:nonNumeric contextRef="From2022-03-14to2022-03-14" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
<span id="xdx_902_edei--DocumentPeriodEndDate_c20220314__20220314_zuyfVFWVV0G6"><ix:nonNumeric contextRef="From2022-03-14to2022-03-14" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 14, 2022</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityRegistrantName_c20220314__20220314_z2c6FpPC01eg"><ix:nonNumeric contextRef="From2022-03-14to2022-03-14" name="dei:EntityRegistrantName">NEKTAR THERAPEUTICS</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact Name of Registrant as Specified in Charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20220314__20220314_zAbkil0SuoO5"><ix:nonNumeric contextRef="From2022-03-14to2022-03-14" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityFileNumber_c20220314__20220314_zZZsi07zZuMj"><ix:nonNumeric contextRef="From2022-03-14to2022-03-14" name="dei:EntityFileNumber">0-24006</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20220314__20220314_zhc6NzSPsAr9"><ix:nonNumeric contextRef="From2022-03-14to2022-03-14" name="dei:EntityTaxIdentificationNumber">94-3134940</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State or Other Jurisdiction <br />
of Incorporation)</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission File Number)</b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS Employer<br />
Identification No.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90E_edei--EntityAddressAddressLine1_c20220314__20220314_zKJiWwAMsdDa"><ix:nonNumeric contextRef="From2022-03-14to2022-03-14" name="dei:EntityAddressAddressLine1">455 Mission Bay Boulevard South</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_903_edei--EntityAddressCityOrTown_c20220314__20220314_znLk9eZjfamj"><ix:nonNumeric contextRef="From2022-03-14to2022-03-14" name="dei:EntityAddressCityOrTown">San Francisco</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressStateOrProvince_c20220314__20220314_zwoq3zOLo8ni"><ix:nonNumeric contextRef="From2022-03-14to2022-03-14" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_907_edei--EntityAddressPostalZipCode_c20220314__20220314_zlJTMWrGgpg"><ix:nonNumeric contextRef="From2022-03-14to2022-03-14" name="dei:EntityAddressPostalZipCode">94158</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address of Principal Executive Offices and
Zip Code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: (<span id="xdx_90F_edei--CityAreaCode_c20220314__20220314_z4C1CIPttxMg"><ix:nonNumeric contextRef="From2022-03-14to2022-03-14" name="dei:CityAreaCode">415</ix:nonNumeric></span>) <span id="xdx_90B_edei--LocalPhoneNumber_c20220314__20220314_zc2vawSzlCD6"><ix:nonNumeric contextRef="From2022-03-14to2022-03-14" name="dei:LocalPhoneNumber">482-5300</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05pt 0pt 0; text-align: left">Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--WrittenCommunications_c20220314__20220314_zQ35i2KPg8Ud"><ix:nonNumeric contextRef="From2022-03-14to2022-03-14" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--SolicitingMaterial_c20220314__20220314_zF5XVwp02UKl"><ix:nonNumeric contextRef="From2022-03-14to2022-03-14" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--PreCommencementTenderOffer_c20220314__20220314_zKfMnBdMfVGd"><ix:nonNumeric contextRef="From2022-03-14to2022-03-14" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--PreCommencementIssuerTenderOffer_c20220314__20220314_z8AXjPG0yDt3"><ix:nonNumeric contextRef="From2022-03-14to2022-03-14" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>Securities registered pursuant to Section 12(b) of the
Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading symbol(s)</b></span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange <br />
on which registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--Security12bTitle_c20220314__20220314_zBPyC9R90Xxj"><ix:nonNumeric contextRef="From2022-03-14to2022-03-14" name="dei:Security12bTitle">Common Stock, $0.0001 par value</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--TradingSymbol_c20220314__20220314_zyMqk2zgaBT4"><ix:nonNumeric contextRef="From2022-03-14to2022-03-14" name="dei:TradingSymbol">NKTR</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--SecurityExchangeName_c20220314__20220314_zzzwGFs1eWjj"><ix:nonNumeric contextRef="From2022-03-14to2022-03-14" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Global Select Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05pt 0pt 0; text-align: justify">Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span id="xdx_90B_edei--EntityEmergingGrowthCompany_c20220314__20220314_zYdXIHZL8rc7"><ix:nonNumeric contextRef="From2022-03-14to2022-03-14" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05pt 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><b>Item
8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 14, 2022,
Nektar Therapeutics (&#8220;Nektar&#8221;) and Bristol-Myers Squibb Company (&#8220;BMS&#8221;) announced that an independent Data
Monitoring Committee (the &#8220;DMC&#8221;) review of the first analysis of the Phase 3 PIVOT IO-001 clinical trial (the
&#8220;PIVOT IO-001 Trial&#8221;) evaluating the doublet therapy bempegaldesleukin, Nektar&#8217;s investigational
CD122-preferential IL-2 pathway agonist drug, in combination with <i>Opdivo</i> (nivolumab) compared to <i>Opdivo</i> monotherapy as
a first-line treatment for previously untreated unresectable or metastatic melanoma, had determined that the PIVOT IO-001 Trial did
not meet the primary endpoints of progression-free survival and objective response rate for&#160;the trial. The DMC also notified Nektar and BMS that the third primary endpoint of overall survival did not meet statistical significance at the
first interim analysis. Based on data reviewed by the
DMC and as further described in the press release, Nektar and BMS have decided to unblind the trial and to perform no additional
analyses for the overall survival endpoint. Additionally, based on the results from the PIVOT IO-001 Trial, Nektar and BMS have also made the decision to stop
enrollment for and unblind the ongoing PIVOT-12 study in adjuvant melanoma, which is evaluating the doublet therapy of
bempegaldesleukin in combination with <i>Opdivo</i> compared to <i>Opdivo</i> monotherapy in patients at high risk for recurrence
after complete resection of melanoma. A copy of the press release issued in connection with the announcement is attached hereto as
Exhibit 99.1, and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit No</b>.</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description&#160;</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea156805ex99-1_nektartherape.htm">Press release titled &#8220;Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with <i>Opdivo</i> (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma.&#8221;</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEKTAR THERAPEUTICS</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 14, 2022</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mark A. Wilson</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark A. Wilson</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General Counsel and Secretary</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwjAQhU/QOwxZizYpuujSoiJWkSLiNtqpBNtMmaT+HMlbGlvEYWAY3vveE2IkVrQ0NTKc5kUOB2zaWnuEAitktBcMjmy9SSHcAq/GedbW9+8PzCgwGJjpWKpzEHrr3TgsU4iTiUwmSoGMUzWD/VZEXz0jW5kSrTe6Bm1L2DO1bNBrfg0JB/0kS82rrzoiO0M2BTmOB/kNKpYKdnTXD+KbgzzPRDTqJxIrpq791nTOUwOLGpvQ5Qb0v9EHFL9JRA== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea156805ex99-1_nektartherape.htm
<DESCRIPTION>PRESS RELEASE TITLED "BRISTOL MYERS SQUIBB AND NEKTAR ANNOUNCE UPDATE ON PHASE 3 PIVOT IO-001 TRIAL EVALUATING BEMPEGALDESLEUKIN (BEMPEG) IN COMBINATION WITH OPDIVO (NIVOLUMAB) IN PREVIOUSLY UNTREATED UNRESECTABLE OR METASTATIC MELANOMA"
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 50%; font-size: 10pt"><IMG SRC="ex99-1_002.jpg" ALT=""></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Bristol Myers Squibb and Nektar Announce Update
on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with <I>Opdivo</I> (nivolumab) in Previously Untreated
Unresectable or Metastatic Melanoma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(PRINCETON, N.J., &amp; SAN FRANCISCO, March 14, 2022) -- Bristol Myers Squibb (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) today announced an update following the first
analysis of the Phase 3 PIVOT IO-001 study evaluating the doublet therapy of bempegaldesleukin in combination with <I>Opdivo</I> (nivolumab)
compared to <I>Opdivo</I> monotherapy as a first-line treatment for previously untreated unresectable or metastatic melanoma. Following
a review of the study for efficacy and safety by an independent Data Monitoring Committee (DMC), Bristol Myers Squibb and Nektar were
informed that the study did not meet the primary endpoints of progression-free survival (PFS) and objective response rate (ORR) as assessed
by Blinded Independent Central Review (BICR). The DMC notified the companies that the third primary endpoint of overall survival (OS)
did not meet statistical significance at the first interim analysis.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Given there was no additional clinical benefit
in the doublet therapy arm compared to the monotherapy arm for the primary endpoints of PFS and ORR, and based on the data reviewed by
the DMC, the companies have decided to unblind the trial and to perform no additional analyses for the OS endpoint. Additionally, based
on the results from PIVOT IO-001, the companies have also made the decision to discontinue enrollment and unblind the ongoing PIVOT-12
study in adjuvant melanoma, which is evaluating the doublet therapy of bempegaldesleukin in combination with <I>Opdivo </I>compared to
<I>Opdivo</I> monotherapy in patients at high risk for recurrence after complete resection of melanoma. Patients in both studies will
be counseled on their treatment options, and permitted to continue treatment if agreed to with their physician.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The companies will review the data and plan to
share the results with the scientific community.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;As a leader in developing innovative therapies
for patients with cancer, we have continued to explore novel strategies that may expand treatment benefits to more patients with advanced
disease,&rdquo; said Jonathan Cheng, senior vice president and head of oncology development, Bristol Myers Squibb. &ldquo;We are disappointed
with the results of this trial, which we had hoped would lead to a new therapeutic option to treat metastatic melanoma. We express our
gratitude to the patients, caregivers and investigators who chose to participate in these trials.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The other four studies ongoing for bempegaldesleukin
plus <I>Opdivo</I> in renal cell carcinoma and bladder cancer are continuing.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;While we are surprised and deeply disappointed
in these results for the melanoma study, we will continue to await initial results from our first two ongoing studies in renal cell carcinoma
and urothelial cancer, which are currently expected in the first half of 2022,&rdquo; said Jonathan Zalevsky, chief research and development
officer of Nektar Therapeutics. &ldquo;We look forward to collaborating with BMS to evaluate the data from these other studies to guide
the future development of bempegaldesleukin. Nektar remains dedicated to the development of therapeutics to treat cancer and auto-immune
disease.&rdquo;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About PIVOT IO-001</U></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">PIVOT IO-001 is a randomized Phase 3 study evaluating
the combination of bempegaldesleukin in combination with <I>Opdivo</I> versus <I>Opdivo</I> alone in patients with previously untreated
unresectable or metastatic melanoma. The study is sponsored and conducted by Bristol-Myers Squibb. A total of 783 patients were randomized
1:1 to receive a combination of bempegaldesleukin 0.006 mg/kg and <I>Opdivo</I> 360 mg or <I>Opdivo</I> 360 mg by intravenous infusion
every three weeks in an outpatient setting. Patients were treated until disease recurrence, unacceptable toxicity or withdrawal of consent
for up to 24 months.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About PIVOT-12</U></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">PIVOT-12 is a randomized Phase 3 open-label study
evaluating the adjuvant immunotherapy of bempegaldesleukin combined with <I>Opdivo</I> versus <I>Opdivo</I> alone after complete resection
of melanoma in patients at high risk for recurrence. The study is sponsored and conducted by Nektar Therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B><U>About&nbsp;Nektar Therapeutics</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">Nektar Therapeutics&nbsp;is
a biopharmaceutical company with a robust, wholly owned R&amp;D pipeline of investigational medicines in oncology, immunology, and virology
as well as a portfolio of approved partnered medicines. Nektar is headquartered in&nbsp;San Francisco,&nbsp;</FONT>California<FONT STYLE="background-color: white">,
with additional operations in&nbsp;Huntsville, Alabama&nbsp;and&nbsp;Hyderabad,&nbsp;</FONT>India<FONT STYLE="background-color: white">.
Further information about the company and its drug development programs and capabilities may be found online at&nbsp;http://www.nektar.com.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Bristol Myers Squibb: Creating a Better Future for People with
Cancer</U></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Bristol Myers Squibb is inspired by a single vision
&mdash; transforming patients&rsquo; lives through science. The goal of the company&rsquo;s cancer research is to deliver medicines that
offer each patient a better, healthier life and to make cure a possibility. Building on a legacy across a broad range of cancers that
have changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine, and
through innovative digital platforms, are turning data into insights that sharpen their focus. Deep scientific expertise, cutting-edge
capabilities and discovery platforms enable the company to look at cancer from every angle. Cancer can have a relentless grasp on many
parts of a patient&rsquo;s life, and Bristol Myers Squibb is committed to taking actions to address all aspects of care, from diagnosis
to survivorship. Because as a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better
future.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About <I>Opdivo</I></U></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Opdivo</I>&nbsp;is a programmed death-1 (PD-1)
immune checkpoint inhibitor that is designed to uniquely harness the body&rsquo;s own immune system to help restore anti-tumor immune
response. By harnessing the body&rsquo;s own immune system to fight cancer,&nbsp;<I>Opdivo</I>&nbsp;has become an important treatment
option across multiple cancers.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Opdivo</I>&rsquo;s leading global development
program is based on Bristol Myers Squibb&rsquo;s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical
trials across all phases, including Phase 3, in a variety of tumor types. To date, the&nbsp;<I>Opdivo</I>&nbsp;clinical development program
has treated more than 35,000 patients. The&nbsp;<I>Opdivo</I>&nbsp;trials have contributed to gaining a deeper understanding of the potential
role of biomarkers in patient care, particularly regarding how patients may benefit from&nbsp;<I>Opdivo</I>&nbsp;across the continuum
of PD-L1 expression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In July 2014,&nbsp;<I>Opdivo</I>&nbsp;was the first
PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world.&nbsp;<I>Opdivo</I>&nbsp;is currently approved in
more than 65 countries, including the United States, the European Union, Japan and China. In October 2015, the Company&rsquo;s <I>Opdivo</I>
and <I>Yervoy </I>combination regimen was the first Immuno-Oncology to receive regulatory approval for the treatment of metastatic melanoma
and is currently approved in more than 50 countries, including the United States and the European Union.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>INDICATIONS</U></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), as a single agent, is indicated
for the treatment of adult patients with unresectable or metastatic melanoma.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), in combination with YERVOY<SUP>&reg;</SUP>
(ipilimumab), is indicated for the treatment of adult patients with unresectable or metastatic melanoma.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab) is indicated for the adjuvant treatment
of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), in combination with platinum-doublet
chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors &ge;4 cm or node positive) non-small cell
lung cancer (NSCLC).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), in combination with YERVOY<SUP>&reg;</SUP>
(ipilimumab), is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors
express PD-L1 (&ge;1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), in combination with YERVOY<SUP>&reg;</SUP>
(ipilimumab) and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic
or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab) is indicated for the treatment of
adult patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with
EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving
OPDIVO.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), in combination with YERVOY<SUP>&reg;</SUP>
(ipilimumab), is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), in combination with YERVOY<SUP>&reg;</SUP>
(ipilimumab), is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma
(RCC).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), in combination with cabozantinib,
is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab) is indicated for the treatment of
adult patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab) is indicated for the treatment of
adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation
(HSCT) and brentuximab vedotin or after 3 or more lines of systemic therapy that includes autologous HSCT. This indication is approved
under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification
and description of clinical benefit in confirmatory trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab) is indicated for the treatment of
adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after
platinum-based therapy.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab) is indicated for the treatment of
adult patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing
chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), as a single agent, is indicated
for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical
resection of UC.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), as a single agent, is indicated
for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair
deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and
irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Continued approval for this indication may be contingent upon verification
and description of clinical benefit in confirmatory trials.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), in combination with YERVOY<SUP>&reg;</SUP>
(ipilimumab), is indicated for the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high
(MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine,
oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response.
Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), in combination with YERVOY<SUP>&reg;</SUP>
(ipilimumab), is indicated for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with
sorafenib. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval
for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab) is indicated for the treatment of
adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine-
and platinum-based chemotherapy.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab) is indicated for the adjuvant treatment
of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received
neoadjuvant chemoradiotherapy (CRT).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO<SUP>&reg;</SUP> (nivolumab), in combination with fluoropyrimidine-
and platinum- containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal
junction cancer, and esophageal adenocarcinoma.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>IMPORTANT SAFETY INFORMATION</U></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Severe and Fatal Immune-Mediated Adverse Reactions</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immune-mediated adverse reactions listed herein may not include all
possible severe and fatal immune-mediated adverse reactions.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immune-mediated adverse reactions, which may be severe or fatal, can
occur in any organ system or tissue. While immune-mediated adverse reactions usually manifest during treatment, they can also occur after
discontinuation of OPDIVO or YERVOY. Early identification and management are essential to ensure safe use of OPDIVO and YERVOY. Monitor
for signs and symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate clinical chemistries
including liver enzymes, creatinine, adrenocorticotropic hormone (ACTH) level, and thyroid function at baseline and periodically during
treatment with OPDIVO and before each dose of YERVOY. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup
to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Withhold or permanently discontinue OPDIVO and YERVOY depending on
severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information). In general, if OPDIVO or YERVOY
interruption or discontinuation is required, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until
improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least
1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled
with corticosteroid therapy. Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g.,
endocrinopathies and dermatologic reactions) are discussed below.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Immune-Mediated Pneumonitis</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO and YERVOY can cause immune-mediated pneumonitis. The incidence
of pneumonitis is higher in patients who have received prior thoracic radiation. In patients receiving OPDIVO monotherapy, immune- mediated
pneumonitis occurred in 3.1% (61/1994) of patients, including Grade 4 (&lt;0.1%), Grade 3 (0.9%), and Grade 2 (2.1%). In patients receiving
OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, immune-mediated pneumonitis occurred in 7% (31/456) of patients, including Grade 4 (0.2%),
Grade 3 (2.0%), and Grade 2 (4.4%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated pneumonitis
occurred in 3.9% (26/666) of patients, including Grade 3 (1.4%) and Grade 2 (2.6%). In NSCLC patients receiving OPDIVO 3 mg/kg every 2
weeks with YERVOY 1 mg/kg every 6 weeks, immune-mediated pneumonitis occurred in 9% (50/576) of patients, including Grade 4 (0.5%), Grade
3 (3.5%), and Grade 2 (4.0%). Four patients (0.7%) died due to pneumonitis.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Checkmate 205 and 039, pneumonitis, including interstitial lung
disease, occurred in 6.0% (16/266) of patients receiving OPDIVO. Immune-mediated pneumonitis occurred in 4.9% (13/266) of patients receiving
OPDIVO, including Grade 3 (n=1) and Grade 2 (n=12).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Immune-Mediated Colitis</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO and YERVOY can cause immune-mediated colitis, which may be fatal.
A common symptom included in the definition of colitis was diarrhea. Cytomegalovirus (CMV) infection/reactivation has been reported in
patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious
workup to exclude alternative etiologies. In patients receiving OPDIVO monotherapy, immune-mediated colitis occurred in 2.9% (58/1994)
of patients, including Grade 3 (1.7%) and Grade 2 (1%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, immune-mediated
colitis occurred in 25% (115/456) of patients, including Grade 4 (0.4%), Grade 3 (14%) and Grade 2 (8%). In patients receiving OPDIVO
3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated colitis occurred in 9% (60/666) of patients, including Grade 3 (4.4%) and Grade
2 (3.7%).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Immune-Mediated Hepatitis and Hepatotoxicity</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO and YERVOY can cause immune-mediated hepatitis. In patients
receiving OPDIVO monotherapy, immune-mediated hepatitis occurred in 1.8% (35/1994) of patients, including Grade 4 (0.2%), Grade 3 (1.3%),
and Grade 2 (0.4%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, immune- mediated hepatitis occurred in 15%
(70/456) of patients, including Grade 4 (2.4%), Grade 3 (11%), and Grade 2 (1.8%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1
mg/kg every 3 weeks, immune-mediated hepatitis occurred in 7% (48/666) of patients, including Grade 4 (1.2%), Grade 3 (4.9%), and Grade
2 (0.4%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO in combination with cabozantinib can cause hepatic toxicity
with higher frequencies of Grade 3 and 4 ALT and AST elevations compared to OPDIVO alone. Consider more frequent monitoring of liver enzymes
as compared to when the drugs are administered as single agents. In patients receiving OPDIVO and cabozantinib, Grades 3 and 4 increased
ALT or AST were seen in 11% of patients.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Immune-Mediated Endocrinopathies</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO and YERVOY can cause primary or secondary adrenal insufficiency,
immune-mediated hypophysitis, immune-mediated thyroid disorders, and Type 1 diabetes mellitus, which can present with diabetic ketoacidosis.
Withhold OPDIVO and YERVOY depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing
Information). For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically
indicated. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects.
Hypophysitis can cause hypopituitarism; initiate hormone replacement as clinically indicated. Thyroiditis can present with or without
endocrinopathy. Hypothyroidism can follow hyperthyroidism; initiate hormone replacement or medical management as clinically indicated.
Monitor patients for hyperglycemia or other signs and symptoms of diabetes; initiate treatment with insulin as clinically indicated.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In patients receiving OPDIVO monotherapy, adrenal insufficiency occurred
in 1% (20/1994), including Grade 3 (0.4%) and Grade 2 (0.6%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks,
adrenal insufficiency occurred in 8% (35/456), including Grade 4 (0.2%), Grade 3 (2.4%), and Grade 2 (4.2%). In patients receiving OPDIVO
3 mg/kg with YERVOY 1 mg/kg every 3 weeks, adrenal insufficiency occurred in 7% (48/666) of patients, including Grade 4 (0.3%), Grade
3 (2.5%), and Grade 2 (4.1%). In patients receiving OPDIVO and cabozantinib, adrenal insufficiency occurred in 4.7% (15/320) of patients,
including Grade 3 (2.2%) and Grade 2 (1.9%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, adrenal insufficiency
occurred in 8% (35/456), including Grade 4 (0.2%), Grade 3 (2.4%), and Grade 2 (4.2%). In patients receiving OPDIVO 3 mg/kg with YERVOY
1 mg/kg every 3 weeks, adrenal insufficiency occurred in 7% (48/666) of patients, including Grade 4 (0.3%), Grade 3 (2.5%), and Grade
2 (4.1%). In patients receiving OPDIVO and cabozantinib, adrenal insufficiency occurred in 4.7% (15/320) of patients, including Grade
3 (2.2%) and Grade 2 (1.9%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In patients receiving OPDIVO monotherapy, hypophysitis occurred in
0.6% (12/1994) of patients, including Grade 3 (0.2%) and Grade 2 (0.3%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every
3 weeks, hypophysitis occurred in 9% (42/456), including Grade 3 (2.4%) and Grade 2 (6%). In patients receiving OPDIVO 3 mg/kg with YERVOY
1 mg/kg every 3 weeks, hypophysitis occurred in 4.4% (29/666) of patients, including Grade 4 (0.3%), Grade 3 (2.4%), and Grade 2 (0.9%).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In patients receiving OPDIVO monotherapy, thyroiditis occurred in 0.6%
(12/1994) of patients, including Grade 2 (0.2%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, thyroiditis occurred
in 2.7% (22/666) of patients, including Grade 3 (4.5%) and Grade 2 (2.2%).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In patients receiving OPDIVO monotherapy, hyperthyroidism occurred
in 2.7% (54/1994) of patients, including Grade 3 (&lt;0.1%) and Grade 2 (1.2%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg
every 3 weeks, hyperthyroidism occurred in 9% (42/456) of patients, including Grade 3 (0.9%) and Grade 2 (4.2%). In patients receiving
OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, hyperthyroidism occurred in 12% (80/666) of patients, including Grade 3 (0.6%) and Grade
2 (4.5%).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In patients receiving OPDIVO monotherapy, hypothyroidism occurred in
8% (163/1994) of patients, including Grade 3 (0.2%) and Grade 2 (4.8%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every
3 weeks, hypothyroidism occurred in 20% (91/456) of patients, including Grade 3 (0.4%) and Grade 2 (11%). In patients receiving OPDIVO
3 mg/kg with YERVOY 1 mg/kg every 3 weeks, hypothyroidism occurred in 18% (122/666) of patients, including Grade 3 (0.6%) and Grade 2
(11%).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In patients receiving OPDIVO monotherapy, diabetes occurred in 0.9%
(17/1994) of patients, including Grade 3 (0.4%) and Grade 2 (0.3%), and 2 cases of diabetic ketoacidosis. In patients receiving OPDIVO
3 mg/kg with YERVOY 1 mg/kg every 3 weeks, diabetes occurred in 2.7% (15/666) of patients, including Grade 4 (0.6%), Grade 3 (0.3%), and
Grade 2 (0.9%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Immune-Mediated Nephritis with Renal Dysfunction</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO and YERVOY can cause immune-mediated nephritis. In patients
receiving OPDIVO monotherapy, immune-mediated nephritis and renal dysfunction occurred in 1.2% (23/1994) of patients, including Grade
4 (&lt;0.1%), Grade 3 (0.5%), and Grade 2 (0.6%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated
nephritis with renal dysfunction occurred in 4.1% (27/666) of patients, including Grade 4 (0.6%), Grade 3 (1.1%), and Grade 2 (2.2%).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Immune-Mediated Dermatologic Adverse Reactions</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO can cause immune-mediated rash or dermatitis. Exfoliative dermatitis,
including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS)
has occurred with PD-1/PD-L1 blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate
nonexfoliative rashes.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">YERVOY can cause immune-mediated rash or dermatitis, including bullous
and exfoliative dermatitis, SJS, TEN, and DRESS. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate
non- bullous/exfoliative rashes.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Withhold or permanently discontinue OPDIVO and YERVOY depending on
severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In patients receiving OPDIVO monotherapy, immune-mediated rash occurred
in 9% (171/1994) of patients, including Grade 3 (1.1%) and Grade 2 (2.2%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every
3 weeks, immune-mediated rash occurred in 28% (127/456) of patients, including Grade 3 (4.8%) and Grade 2 (10%). In patients receiving
OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated rash occurred in 16% (108/666) of patients, including Grade 3 (3.5%)
and Grade 2 (4.2%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Other Immune-Mediated Adverse Reactions</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following clinically significant immune-mediated adverse reactions
occurred at an incidence of &lt;1% (unless otherwise noted) in patients who received OPDIVO monotherapy or OPDIVO in combination with
YERVOY or were reported with the use of other PD-1/PD-L1 blocking antibodies. Severe or fatal cases have been reported for some of these
adverse reactions: <I>cardiac/vascular: </I>myocarditis, pericarditis, vasculitis; <I>nervous system: </I>meningitis, encephalitis, myelitis
and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barr&eacute; syndrome, nerve paresis, autoimmune
neuropathy; <I>ocular: </I>uveitis, iritis, and other ocular inflammatory toxicities can occur; <I>gastrointestinal: </I>pancreatitis
to include increases in serum amylase and lipase levels, gastritis, duodenitis; <I>musculoskeletal and connective tissue: </I>myositis/polymyositis,
rhabdomyolysis, and associated sequelae including renal failure, arthritis, polymyalgia rheumatica; <I>endocrine: </I>hypoparathyroidism;
<I>other (hematologic/immune): </I>hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis (HLH), systemic inflammatory
response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid
organ transplant rejection.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the immune-mediated adverse reactions listed above,
across clinical trials of YERVOY monotherapy or in combination with OPDIVO, the following clinically significant immune-mediated adverse
reactions, some with fatal outcome, occurred in &lt;1% of patients unless otherwise specified: <I>nervous system: </I>autoimmune neuropathy
(2%), myasthenic syndrome/myasthenia gravis, motor dysfunction; <I>cardiovascular: </I>angiopathy, temporal arteritis; <I>ocular: </I>blepharitis,
episcleritis, orbital myositis, scleritis; <I>gastrointestinal: </I>pancreatitis (1.3%); <I>other (hematologic/immune): </I>conjunctivitis,
cytopenias (2.5%), eosinophilia (2.1%), erythema multiforme, hypersensitivity vasculitis, neurosensory hypoacusis, psoriasis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some ocular IMAR cases can be associated with retinal detachment. Various
grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions,
consider a Vogt-Koyanagi-Harada&ndash;like syndrome, which has been observed in patients receiving OPDIVO and YERVOY, as this may require
treatment with systemic corticosteroids to reduce the risk of permanent vision loss.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Infusion-Related Reactions</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OPDIVO and YERVOY can cause severe infusion-related reactions. Discontinue
OPDIVO and YERVOY in patients with severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions. Interrupt or slow the rate
of infusion in patients with mild (Grade 1) or moderate (Grade 2) infusion-related reactions. In patients receiving OPDIVO monotherapy
as a 60-minute infusion, infusion-related reactions occurred in 6.4% (127/1994) of patients. In a separate trial in which patients received
OPDIVO monotherapy as a 60-minute infusion or a 30- minute infusion, infusion-related reactions occurred in 2.2% (8/368) and 2.7% (10/369)
of patients, respectively. Additionally, 0.5% (2/368) and 1.4% (5/369) of patients, respectively, experienced adverse reactions within
48 hours of infusion that led to dose delay, permanent discontinuation or withholding of OPDIVO. In melanoma patients receiving OPDIVO
1 mg/kg with YERVOY 3 mg/kg every 3 weeks, infusion-related reactions occurred in 2.5% (10/407) of patients. In HCC patients receiving
OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, infusion-related reactions occurred in 8% (4/49) of patients. In RCC patients receiving
OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, infusion-related reactions occurred in 5.1% (28/547) of patients. In MSI- H/dMMR mCRC
patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, infusion-related reactions occurred in 4.2% (5/119) of patients.
In MPM patients receiving OPDIVO 3 mg/kg every 2 weeks with YERVOY 1 mg/kg every 6 weeks, infusion-related reactions occurred in 12% (37/300)
of patients.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Complications of Allogeneic Hematopoietic Stem Cell Transplantation</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fatal and other serious complications can occur in patients who receive
allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with OPDIVO or YERVOY. Transplant-related complications
include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity
conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening
therapy between OPDIVO or YERVOY and allogeneic HSCT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Follow patients closely for evidence of transplant-related complications
and intervene promptly. Consider the benefit versus risks of treatment with OPDIVO and YERVOY prior to or after an allogeneic HSCT.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Embryo-Fetal Toxicity</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on its mechanism of action and findings from animal studies,
OPDIVO and YERVOY can cause fetal harm when administered to a pregnant woman. The effects of YERVOY are likely to be greater during the
second and third trimesters of pregnancy. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential
to use effective contraception during treatment with OPDIVO and YERVOY and for at least 5 months after the last dose.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Increased Mortality in Patients with Multiple Myeloma when OPDIVO
is Added to a Thalidomide Analogue and Dexamethasone</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In randomized clinical trials in patients with multiple myeloma, the
addition of OPDIVO to a thalidomide analogue plus dexamethasone resulted in increased mortality. Treatment of patients with multiple myeloma
with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled
clinical trials.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lactation</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no data on the presence of OPDIVO or YERVOY in human milk,
the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in breastfed
children, advise women not to breastfeed during treatment and for 5 months after the last dose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Serious Adverse Reactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Checkmate 037, serious adverse reactions occurred in 41% of patients
receiving OPDIVO (n=268). Grade 3 and 4 adverse reactions occurred in 42% of patients receiving OPDIVO. The most frequent Grade 3 and
4 adverse drug reactions reported in 2% to &lt;5% of patients receiving OPDIVO were abdominal pain, hyponatremia, increased aspartate
aminotransferase, and increased lipase. In Checkmate 066, serious adverse reactions occurred in 36% of patients receiving OPDIVO (n=206).
Grade 3 and 4 adverse reactions occurred in 41% of patients receiving OPDIVO. The most frequent Grade 3 and 4 adverse reactions reported
in &ge;2% of patients receiving OPDIVO were gamma-glutamyltransferase increase (3.9%) and diarrhea (3.4%). In Checkmate 067, serious adverse
reactions (74% and 44%), adverse reactions leading to permanent discontinuation (47% and 18%) or to dosing delays (58% and 36%), and Grade
3 or 4 adverse reactions (72% and 51%) all occurred more frequently in the OPDIVO plus YERVOY arm (n=313) relative to the OPDIVO arm (n=313).
The most frequent (&ge;10%) serious adverse reactions in the OPDIVO plus YERVOY arm and the OPDIVO arm, respectively, were diarrhea (13%
and 2.2%), colitis (10% and 1.9%), and pyrexia (10% and 1.0%). In Checkmate 238, serious adverse reactions occurred in 18% of patients
receiving OPDIVO (n=452). Grade 3 or 4 adverse reactions occurred in 25% of OPDIVO-treated patients (n=452). The most frequent Grade 3
and 4 adverse reactions reported in &ge;2% of OPDIVO-treated patients were diarrhea and increased lipase and amylase. In Checkmate 816,
serious adverse reactions occurred in 30% of patients (n=176) who were treated with OPDIVO in combination with platinum-doublet chemotherapy.
Serious adverse reactions in &gt;2% included pneumonia and vomiting. No fatal adverse reactions occurred in patients who received OPDIVO
in combination with platinum-doublet chemotherapy. In Checkmate 227, serious adverse reactions occurred in 58% of patients (n=576). The
most frequent (&ge;2%) serious adverse reactions were pneumonia, diarrhea/colitis, pneumonitis, hepatitis, pulmonary embolism, adrenal
insufficiency, and hypophysitis. Fatal adverse reactions occurred in 1.7% of patients; these included events of pneumonitis (4 patients),
myocarditis, acute kidney injury, shock, hyperglycemia, multi-system organ failure, and renal failure. In Checkmate 9LA, serious adverse
reactions occurred in 57% of patients (n=358). The most frequent (&gt;2%) serious adverse reactions were pneumonia, diarrhea, febrile
neutropenia, anemia, acute kidney injury, musculoskeletal pain, dyspnea, pneumonitis, and respiratory failure. Fatal adverse reactions
occurred in 7 (2%) patients, and included hepatic toxicity, acute renal failure, sepsis, pneumonitis, diarrhea with hypokalemia, and massive
hemoptysis in the setting of thrombocytopenia. In Checkmate 017 and 057, serious adverse reactions occurred in 46% of patients receiving
OPDIVO (n=418). The most frequent serious adverse reactions reported in &ge;2% of patients receiving OPDIVO were pneumonia, pulmonary
embolism, dyspnea, pyrexia, pleural effusion, pneumonitis, and respiratory failure. In Checkmate 057, fatal adverse reactions occurred;
these included events of infection (7 patients, including one case of <I>Pneumocystis jirovecii </I>pneumonia), pulmonary embolism (4
patients), and limbic encephalitis (1 patient). In Checkmate 743, serious adverse reactions occurred in 54% of patients receiving OPDIVO
plus YERVOY. The most frequent serious adverse reactions reported in &ge;2% of patients were pneumonia, pyrexia, diarrhea, pneumonitis,
pleural effusion, dyspnea, acute kidney injury, infusion-related reaction, musculoskeletal pain, and pulmonary embolism. Fatal adverse
reactions occurred in 4 (1.3%) patients and included pneumonitis, acute heart failure, sepsis, and encephalitis. In Checkmate 214, serious
adverse reactions occurred in 59% of patients receiving OPDIVO plus YERVOY (n=547). The most frequent serious adverse reactions reported
in &ge;2% of patients were diarrhea, pyrexia, pneumonia, pneumonitis, hypophysitis, acute kidney injury, dyspnea, adrenal insufficiency,
and colitis. In Checkmate 9ER, serious adverse reactions occurred in 48% of patients receiving OPDIVO and cabozantinib (n=320). The most
frequent serious adverse reactions reported in &ge;2% of patients were diarrhea, pneumonia, pneumonitis, pulmonary embolism, urinary tract
infection, and hyponatremia. Fatal intestinal perforations occurred in 3 (0.9%) patients. In Checkmate 025, serious adverse reactions
occurred in 47% of patients receiving OPDIVO (n=406). The most frequent serious adverse reactions reported in &ge;2% of patients were
acute kidney injury, pleural effusion, pneumonia, diarrhea, and hypercalcemia. In Checkmate 205 and 039, adverse reactions leading to
discontinuation occurred in 7% and dose delays due to adverse reactions occurred in 34% of patients (n=266). Serious adverse reactions
occurred in 26% of patients. The most frequent serious adverse reactions reported in &ge;1% of patients were pneumonia, infusion-related
reaction, pyrexia, colitis or diarrhea, pleural effusion, pneumonitis, and rash. Eleven patients died from causes other than disease progression:
3 from adverse reactions within 30 days of the last OPDIVO dose, 2 from infection 8 to 9 months after completing OPDIVO, and 6 from complications
of allogeneic HSCT. In Checkmate 141, serious adverse reactions occurred in 49% of patients receiving OPDIVO (n=236). The most frequent
serious adverse reactions reported in &ge;2% of patients receiving OPDIVO were pneumonia, dyspnea, respiratory failure, respiratory tract
infection, and sepsis. In Checkmate 275, serious adverse reactions occurred in 54% of patients receiving OPDIVO (n=270). The most frequent
serious adverse reactions reported in &ge;2% of patients receiving OPDIVO were urinary tract infection, sepsis, diarrhea, small intestine
obstruction, and general physical health deterioration. In Checkmate 274, serious adverse reactions occurred in 30% of patients receiving
OPDIVO (n=351). The most frequent serious adverse reaction reported in &ge;2% of patients receiving OPDIVO was urinary tract infection.
Fatal adverse reactions occurred in 1% of patients; these included events of pneumonitis (0.6%). In Checkmate 142 in MSI-H/dMMR mCRC patients
receiving OPDIVO with YERVOY (n=119), serious adverse reactions occurred in 47% of patients. The most frequent serious adverse reactions
reported in &ge;2% of patients were colitis/diarrhea, hepatic events, abdominal pain, acute kidney injury, pyrexia, and dehydration. In
Checkmate 040, serious adverse reactions occurred in 59% of patients receiving OPDIVO with YERVOY (n=49). Serious adverse reactions reported
in &ge;4% of patients were pyrexia, diarrhea, anemia, increased AST, adrenal insufficiency, ascites, esophageal varices hemorrhage, hyponatremia,
increased blood bilirubin, and pneumonitis. In Attraction-3, serious adverse reactions occurred in 38% of patients receiving OPDIVO (n=209).
Serious adverse reactions reported in &ge;2% of patients who received OPDIVO were pneumonia, esophageal fistula, interstitial lung disease,
and pyrexia. The following fatal adverse reactions occurred in patients who received OPDIVO: interstitial lung disease or pneumonitis
(1.4%), pneumonia (1.0%), septic shock (0.5%), esophageal fistula (0.5%), gastrointestinal hemorrhage (0.5%), pulmonary embolism (0.5%),
and sudden death (0.5%). In Checkmate 577, serious adverse reactions occurred in 33% of patients receiving OPDIVO (n=532). A serious adverse
reaction reported in &ge;2% of patients who received OPDIVO was pneumonitis. A fatal reaction of myocardial infarction occurred in one
patient who received OPDIVO. In Checkmate 649, serious adverse reactions occurred in 52% of patients treated with OPDIVO in combination
with chemotherapy (n=782). The most frequent serious adverse reactions reported in &ge;2% of patients treated with OPDIVO in combination
with chemotherapy were vomiting (3.7%), pneumonia (3.6%), anemia (3.6%), pyrexia (2.8%), diarrhea (2.7%), febrile neutropenia (2.6%),
and pneumonitis (2.4%). Fatal adverse reactions occurred in 16 (2.0%) patients who were treated with OPDIVO in combination with chemotherapy;
these included pneumonitis (4 patients), febrile neutropenia (2 patients), stroke (2 patients), gastrointestinal toxicity, intestinal
mucositis, septic shock, pneumonia, infection, gastrointestinal bleeding, mesenteric vessel thrombosis, and disseminated intravascular
coagulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Adverse Reactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Checkmate 037, the most common adverse reaction (&ge;20%) reported
with OPDIVO (n=268) was rash (21%). In Checkmate 066, the most common adverse reactions (&ge;20%) reported with OPDIVO (n=206) vs dacarbazine
(n=205) were fatigue (49% vs 39%), musculoskeletal pain (32% vs 25%), rash (28% vs 12%), and pruritus (23% vs 12%). In Checkmate 067,
the most common (&ge;20%) adverse reactions in the OPDIVO plus YERVOY arm (n=313) were fatigue (62%), diarrhea (54%), rash (53%), nausea
(44%), pyrexia (40%), pruritus (39%), musculoskeletal pain (32%), vomiting (31%), decreased appetite (29%), cough (27%), headache (26%),
dyspnea (24%), upper respiratory tract infection (23%), arthralgia (21%), and increased transaminases (25%). In Checkmate 067, the most
common (&ge;20%) adverse reactions in the OPDIVO arm (n=313) were fatigue (59%), rash (40%), musculoskeletal pain (42%), diarrhea (36%),
nausea (30%), cough (28%), pruritus (27%), upper respiratory tract infection (22%), decreased appetite (22%), headache (22%), constipation
(21%), arthralgia (21%), and vomiting (20%). In Checkmate 238, the most common adverse reactions (&ge;20%) reported in OPDIVO- treated
patients (n=452) vs ipilimumab-treated patients (n=453) were fatigue (57% vs 55%), diarrhea (37% vs 55%), rash (35% vs 47%), musculoskeletal
pain (32% vs 27%), pruritus (28% vs 37%), headache (23% vs 31%), nausea (23% vs 28%), upper respiratory infection (22% vs 15%), and abdominal
pain (21% vs 23%). The most common immune-mediated adverse reactions were rash (16%), diarrhea/colitis (6%), and hepatitis (3%). In Checkmate
816, the most common (&gt;20%) adverse reactions in the OPDIVO plus chemotherapy arm (n=176) were nausea (38%), constipation (34%), fatigue
(26%), decreased appetite (20%), and rash (20%). In Checkmate 227, the most common (&ge;20%) adverse reactions were fatigue (44%), rash
(34%), decreased appetite (31%), musculoskeletal pain (27%), diarrhea/colitis (26%), dyspnea (26%), cough (23%), hepatitis (21%), nausea
(21%), and pruritus (21%). In Checkmate 9LA, the most common (&gt;20%) adverse reactions were fatigue (49%), musculoskeletal pain (39%),
nausea (32%), diarrhea (31%), rash (30%), decreased appetite (28%), constipation (21%), and pruritus (21%). In Checkmate 017 and 057,
the most common adverse reactions (&ge;20%) in patients receiving OPDIVO (n=418) were fatigue, musculoskeletal pain, cough, dyspnea, and
decreased appetite. In Checkmate 743, the most common adverse reactions (&ge;20%) in patients receiving OPDIVO plus YERVOY were fatigue
(43%), musculoskeletal pain (38%), rash (34%), diarrhea (32%), dyspnea (27%), nausea (24%), decreased appetite (24%), cough (23%), and
pruritus (21%). In Checkmate 214, the most common adverse reactions (&ge;20%) reported in patients treated with OPDIVO plus YERVOY (n=547)
were fatigue (58%), rash (39%), diarrhea (38%), musculoskeletal pain (37%), pruritus (33%), nausea (30%), cough (28%), pyrexia (25%),
arthralgia (23%), decreased appetite (21%), dyspnea (20%), and vomiting (20%). In Checkmate 9ER, the most common adverse reactions (&ge;20%)
in patients receiving OPDIVO and cabozantinib (n=320) were diarrhea (64%), fatigue (51%), hepatotoxicity (44%), palmar-plantar erythrodysaesthesia
syndrome (40%), stomatitis (37%), rash (36%), hypertension (36%), hypothyroidism (34%), musculoskeletal pain (33%), decreased appetite
(28%), nausea (27%), dysgeusia (24%), abdominal pain (22%), cough (20%) and upper respiratory tract infection (20%). In Checkmate 025,
the most common adverse reactions (&ge;20%) reported in patients receiving OPDIVO (n=406) vs everolimus (n=397) were fatigue (56% vs 57%),
cough (34% vs 38%), nausea (28% vs 29%), rash (28% vs 36%), dyspnea (27% vs 31%), diarrhea (25% vs 32%), constipation (23% vs 18%), decreased
appetite (23% vs 30%), back pain (21% vs 16%), and arthralgia (20% vs 14%). In Checkmate 205 and 039, the most common adverse reactions
(&ge;20%) reported in patients receiving OPDIVO (n=266) were upper respiratory tract infection (44%), fatigue (39%), cough (36%), diarrhea
(33%), pyrexia (29%), musculoskeletal pain (26%), rash (24%), nausea (20%) and pruritus (20%). In Checkmate 141, the most common adverse
reactions (&ge;10%) in patients receiving OPDIVO (n=236) were cough (14%) and dyspnea (14%) at a higher incidence than investigator&rsquo;s
choice. In Checkmate 275, the most common adverse reactions (&ge;20%) reported in patients receiving OPDIVO (n=270) were fatigue (46%),
musculoskeletal pain (30%), nausea (22%), and decreased appetite (22%). In Checkmate 274, the most common adverse reactions (&ge;20%)
reported in patients receiving OPDIVO (n=351) were rash (36%), fatigue (36%), diarrhea (30%), pruritus (30%), musculoskeletal pain (28%),
and urinary tract infection (22%). In Checkmate 142 in MSI-H/dMMR mCRC patients receiving OPDIVO as a single agent (n=74), the most common
adverse reactions (&ge;20%) were fatigue (54%), diarrhea (43%), abdominal pain (34%), nausea (34%), vomiting (28%), musculoskeletal pain
(28%), cough (26%), pyrexia (24%), rash (23%), constipation (20%), and upper respiratory tract infection (20%). In Checkmate 142 in MSI-H/dMMR
mCRC patients receiving OPDIVO with YERVOY (n=119), the most common adverse reactions (&ge;20%) were fatigue (49%), diarrhea (45%), pyrexia
(36%), musculoskeletal pain (36%), abdominal pain (30%), pruritus (28%), nausea (26%), rash (25%), decreased appetite (20%), and vomiting
(20%). In Checkmate 040, the most common adverse reactions (&ge;20%) in patients receiving OPDIVO with YERVOY (n=49), were rash (53%),
pruritus (53%), musculoskeletal pain (41%), diarrhea (39%), cough (37%), decreased appetite (35%), fatigue (27%), pyrexia (27%), abdominal
pain (22%), headache (22%), nausea (20%), dizziness (20%), hypothyroidism (20%), and weight decreased (20%). In Attraction-3, the most
common adverse reactions (&ge;20%) in OPDIVO-treated patients (n=209) were rash (22%) and decreased appetite (21%). In Checkmate 577,
the most common adverse reactions (&ge;20%) in patients receiving OPDIVO (n=532) were fatigue (34%), diarrhea (29%), nausea (23%), rash
(21%), musculoskeletal pain (21%), and cough (20%). In Checkmate 649, the most common adverse reactions (&ge;20%) in patients treated
with OPDIVO in combination with chemotherapy (n=782) were peripheral neuropathy (53%), nausea (48%), fatigue (44%), diarrhea (39%), vomiting
(31%), decreased appetite (29%), abdominal pain (27%), constipation (25%), and musculoskeletal pain (20%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please see US Full Prescribing Information for OPDIVO and YERVOY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Clinical Trials and Patient Populations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Checkmate 037&ndash;previously treated metastatic melanoma; Checkmate
066&mdash;previously untreated metastatic melanoma; Checkmate 067&ndash;previously untreated metastatic melanoma, as a single agent or
in combination with YERVOY; Checkmate 238&ndash;adjuvant treatment of melanoma; Checkmate 816&ndash;neoadjuvant non-small cell lung cancer,
in combination with platinum-doublet chemotherapy; Checkmate 227&mdash;previously untreated metastatic non-small cell lung cancer, in
combination with YERVOY; Checkmate 9LA&ndash;previously untreated recurrent or metastatic non-small cell lung cancer in combination with
YERVOY and 2 cycles of platinum-doublet chemotherapy by histology; Checkmate 017&ndash;second-line treatment of metastatic squamous non-small
cell lung cancer; Checkmate 057&ndash;second-line treatment of metastatic non-squamous non-small cell lung cancer; Checkmate 743&ndash;previously
untreated unresectable malignant pleural mesothelioma, in combination with YERVOY; Checkmate 214&ndash;previously untreated renal cell
carcinoma, in combination with YERVOY; Checkmate 9ER&ndash;previously untreated renal cell carcinoma, in combination with cabozantinib;
Checkmate 025&ndash;previously treated renal cell carcinoma; Checkmate 205/039&ndash;classical Hodgkin lymphoma; Checkmate 141&ndash;recurrent
or metastatic squamous cell carcinoma of the head and neck; Checkmate 275&ndash;previously treated advanced or metastatic urothelial carcinoma;
Checkmate 274&ndash;adjuvant treatment of urothelial carcinoma; Checkmate 142&ndash; MSI-H or dMMR metastatic colorectal cancer, as a
single agent or in combination with YERVOY; Checkmate 142&ndash;MSI-H or dMMR metastatic colorectal cancer, as a single agent or in combination
with YERVOY; Checkmate 040&ndash;hepatocellular carcinoma, in combination with YERVOY; Attraction-3&ndash;esophageal squamous cell carcinoma;
Checkmate 577&ndash;adjuvant treatment of esophageal or gastroesophageal junction cancer; Checkmate 649&ndash; previously untreated advanced
or metastatic gastric or gastroesophageal junction or esophageal adenocarcinoma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About the Bristol Myers Squibb and Ono Pharmaceutical Collaboration</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In 2011, through a collaboration agreement with
Ono Pharmaceutical Co., Bristol Myers Squibb expanded its territorial rights to develop and commercialize <I>Opdivo</I> globally, except
in Japan, South Korea and Taiwan, where Ono had retained all rights to the compound at the time. On July 23, 2014, Ono and Bristol Myers
Squibb further expanded the companies&rsquo; strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies
&ndash; as single agents and combination regimens &ndash; for patients with cancer in Japan, South Korea and Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About Bristol Myers Squibb</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Bristol Myers Squibb is a
global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over
serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook
and Instagram.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Celgene and Juno Therapeutics are wholly owned
subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics
are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Cautionary Statement Regarding Forward-Looking Statements</U></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>This press release contains &ldquo;forward-looking
statements&rdquo; within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research,
development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may
be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations
and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties,
including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to
predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from
those expressed in, or implied by, the statements.&nbsp;Among other risks, there can be no guarantee that the collaboration with Nektar
will progress as contemplated in this release or that NKTR-214, alone or in combination with Opdivo or Opdivo plus Yervoy will receive
regulatory approval for the treatment of cancer. No forward-looking statement can be guaranteed. Forward-looking statements in this press
release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb&rsquo;s business and market,
particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb&rsquo;s Annual Report on
Form 10-K for the year ended&nbsp;December 31, 2021, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on
Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are
made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation
to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances
or otherwise.&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Cautionary Note Regarding Forward-Looking Statements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>This press release contains forward-looking statements which can
be identified by words such as: &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;design,&rdquo; &ldquo;potential,&rdquo; &ldquo;initiate,&rdquo; &ldquo;plan,&rdquo;
&ldquo;advance&rdquo; and similar references to future periods. Examples of forward-looking statements include, among others, statements
we make regarding the future development plans and the timing of data readouts for bempegaldesleukin. Forward-looking statements are neither
historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions
regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions.
Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances
that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated
in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could
cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) our statements
regarding the therapeutic potential of bempegaldesleukin are based on preclinical and clinical findings and observations and are subject
to change as research and development continue; (ii) bempegaldesleukin is an investigational agent and continued research and development
for this drug candidate is subject to substantial risks, including negative safety and efficacy findings in ongoing clinical studies (notwithstanding
positive findings in earlier preclinical and clinical studies); (iii) bempegaldesleukin remains in clinical development and the risk of
clinical failure is high and can unexpectedly occur at any stage prior to regulatory approval; (iv) the timing of the end of clinical
trials and the availability of clinical data may be delayed or unsuccessful due; (v) patents may not issue from our patent applications
for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties
may be required; and (vi) certain other important risks and uncertainties set forth in our Annual Report on Form 10-K filed with the Securities
and Exchange Commission on February 28, 2022. Any forward-looking statement made by us in this press release is based only on information
currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking
statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or
otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>corporatefinancial-news</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Bristol Myers Squibb</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Inquiries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">media@bms.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investors:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">investor.relations@bms.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nektar: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Inquiries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dan Budwick&nbsp;of 1AB<BR>
973-271-6085</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">dan@1abmedia.com<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investors:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vivian Wu&nbsp;of Nektar Therapeutics<BR>
628-895-0661</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">20</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: center; margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  B .0# 2(  A$! Q$!_\0
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D0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  > 'D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#T*+QM>QZE
MLN4A-LLI5]JD,%SC/6N[1UD175@RL,@CN*\E@L9-1U*X@AYD'F.H_O8.<5UO
M@O6/.A.F3L?,B&8L]U[C\*\O!XF;GRU'OM_D>MC<+!04Z:U25UZ]35\3:I<:
M1IJ7%L$+F4)\XR,8-<LOC+6G&4@B8>JQ$UN>.?\ D!Q_]=U_D:QO#OB:TTC3
M3;3Q3,YD+Y0#&#CWHQ%62Q')S\JL+#4HO#\ZI\SN$?B[7&D13;)@L ?W+>M7
MF\3WX\3G3@L/D?:?*^Z<XS]:O6GC*PO+R&VC@N \KA%+ 8!/XUR5]<+:>,9[
MEP66*[+D#J<&HJ590@I1J<RNBZ=*-2;C*ERNS._UC5X-'LS-,<N>(XQU<_X5
MQR^,M:D&Y((F&?X8F(K.:[/B#7XFOY_)BD?:,=$7L!Z?6O3;:VAL[=+>",)$
M@PJBM83J8J3<)<L493IT\)%*I'FD_N1P)\:ZPK;3' &]#&<_SJ[IOBC6;K4[
M:":W0122!6(A88!K,UG_ )'9_P#KXC_]EKO-8OAINE7%UGYD0[?=CP/UK.C[
M63DY5':+-*_LHQ@HTU>2^XY35O&-[;:I<06BPF&)M@++DDCKW]:["PNUO]/@
MND^[*@;Z'N*\XTS1WU#1]2O3DO" 4]V'+?I71>!+_P VRGLF/S1-O0?[)_\
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3"<*?+/H_P,,;4A4J\\.J7WG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>nktr-20220314.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kk5s7xRiXhun8uNbHcsWaePKaPtzp95uYlBuGl7fVk6nyAjOml5CSCnbvj2QfoJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:NKTR="http://nektar.com/20220314" elementFormDefault="qualified" targetNamespace="http://nektar.com/20220314">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://nektar.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="nktr-20220314_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="nktr-20220314_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>nktr-20220314_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>nktr-20220314_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nektar.com/role/Cover" xlink:href="nktr-20220314.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://nektar.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139969159445736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 14, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 14,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-24006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEKTAR THERAPEUTICS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000906709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3134940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">455 Mission Bay Boulevard South<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">482-5300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NKTR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>ea156805-8k_nektarther_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nktr-20220314.xsd" xlink:type="simple"/>
    <context id="From2022-03-14to2022-03-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2022-03-14</startDate>
            <endDate>2022-03-14</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-03-14to2022-03-14">0000906709</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-03-14to2022-03-14">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-03-14to2022-03-14">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-03-14to2022-03-14">2022-03-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-03-14to2022-03-14">NEKTAR THERAPEUTICS</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-03-14to2022-03-14">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-03-14to2022-03-14">0-24006</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-03-14to2022-03-14">94-3134940</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-03-14to2022-03-14">455 Mission Bay Boulevard South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-03-14to2022-03-14">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-03-14to2022-03-14">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-03-14to2022-03-14">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-03-14to2022-03-14">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-03-14to2022-03-14">482-5300</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-03-14to2022-03-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-03-14to2022-03-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-03-14to2022-03-14">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-03-14to2022-03-14">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-03-14to2022-03-14">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-03-14to2022-03-14">NKTR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-03-14to2022-03-14">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-03-14to2022-03-14">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "\.6Y4JL0B%C,!   B @
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M-_=%KLWC":[?#'!X=/X!4$L#!!0    ( +PY;E1ED'F2&0$  ,\#   3
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "\.6Y4)!Z;HJT   #X 0
M&@              @ &?$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " "\.6Y499!YDAD!  #/ P  $P              @ &$$@
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #.$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>122</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea156805-8k_nektarther.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nektar.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ea156805-8k_nektarther.htm">ea156805-8k_nektarther.htm</File>
    <File>ea156805ex99-1_nektartherape.htm</File>
    <File>nktr-20220314.xsd</File>
    <File>nktr-20220314_lab.xml</File>
    <File>nktr-20220314_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea156805-8k_nektarther.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ea156805-8k_nektarther.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nktr-20220314_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nktr-20220314_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nktr-20220314.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 122,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "NKTR",
   "nsuri": "http://nektar.com/20220314",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea156805-8k_nektarther.htm",
      "contextRef": "From2022-03-14to2022-03-14",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://nektar.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea156805-8k_nektarther.htm",
      "contextRef": "From2022-03-14to2022-03-14",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://nektar.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001213900-22-011983-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-22-011983-xbrl.zip
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MFX5!:&=R8N7(^O=\+]"*J6]&:* M1FJ>$V9J"9/^5:;+64Z7,T.7;?7: HC
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M:,5QZ'LNK;"6)8A9>7>.(.OIU"Q'_",%,%@ /%57BSGM\S1RAM[HJ7KOS+0
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MV3R\A1.1%C'/^9@=A]XP,))#T6R(B_,;] R4[-(OP[^_MOA$"0166P3IB\J
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M.@0[1W*TO?R\XC;7SL79H\E0@[>1,PS_1*0Y\(:M9N,O(V@M&M0C%NXK(K>
M:^[W,.YPUT@;3B1P@HD7DI2#C#/R\!$/=\?#R'=(["-\_29T)[@+POXH1L+H
MS=M=R09!%#O27!G0939E] 7X35A-P45&/YS@FA1I* Z9(Z&GH?]PK@9CE[,&
M4;%#4N.(A;VY/+L2W7D(Y37]Y-%.%.$Y3+R""M1GMQC"%3ZG -))E1R0'/4F
M9R5+#LA7@SD07L_! U:!]!BCW^"&&Y*P<.O*1VXP]F1C+5DZ@RT'5:I3U59G
M60&,2GBF/)W)T)4 .)SG*J51<+.&2T8)..2*;#R*O+F]SU:MCB0<+R#^-9.@
MD"G3\$]W#!P\.@:,8^#@T3'P[?#6W"PO^_7C/U)G!N94D7HF78>KU8 ;!)KH
M=^?R[.S->V,EKK#7+*M$E8>2N?@H&>^//3\<H0Y;KJF4D5@JI6 QF&DL=8AR
M4T[L#J-",<P,7Y -DLQ5CE+@]94C8ITD$KH]<_$7%%0,8H NE@,:Y=A(/G'9
MN? ]D\P=PMW;!XQJ"6;G%Z/G(C>_=#DV'"^7K#/Q/^ J<ES)=BQ5K_OE[!%O
M]TY3D$)],,4C.M\[=*H6VC'ULT*?(+];=?-Y2&ZD<7W?X^)9Q!KD5LD>XW'G
MW>7YWIM=9AQ>3"K;"#)A[GC$J%W2YS@+5NVX[]Y=[!99"U\=@__&SUR%9Q=G
M!56\H'X7ZNJ6#[BCQGX:1N%\$7DSS^6[(N$G@K.<?'-QQ".6%"::IEFK)*M[
MZ\AR"R05=Z$0M4GY_MR$^M7JYM_3>?SLJ2QQY=AF)W3Y^&YU:&D9*T^M^CL.
M;;-1/;7J;SRTS<;#'2OU>*J^UE-5$713(O\DA+6"6P%%]>5-R4\WU#HHEA&R
M%Q\D/!6'D3/6@3?\XE1;XZ>QFL!GHUISX^&;\]4</OIJC*_F\-%7\_4QQ_M:
M^Z68J37Y6RM=.#I&'8Z)1N7_%=Z<G5>78(XFC,^!BZIPWQ/-<EV,_WL6='?*
MN[49L7QG+9;RE04LT<<30EX4%I[]G@9B.1N%S>9U>FZ*B_-.,D44H9"(R\7O
MR[13#5$U&T4'#*,2IGKFSB&E\.K[CAC6JR^;CH9:X:>ZKTJSPJO'- )MWE1'
MK=),LU$A&M'("T3E$#C"C M\6W=CWGW\<'%UBG(WIZ]?7?VFSM^__G#QCF_+
M?"6791Y\LDO4H!#5\K4#XXYO:^F]=Y*SX:I3%P7RM+K0ID;$5P"%SW_,#11F
M%@J.@4)DH:!\+\8/N./GB6*-OCDF1(M;V<V&E&$A>1OG0!XSD+U-PW_#''0C
M:&W-9F.L&.!!O0#L4/H?!1A'I+A(65+$$"9.8 LG@$-Z<9R26205K3<"6Z5Q
MRJ$0VJ4WUG%B0QD9E^6[D0NNS<*=9V1V$Y/*.\YDEIE("2Q%S-:V>L6WS;EE
M0]G4HCF)L4J/&A3(B6.YR\Y54((8!7W0"$NAJ$H^,KZT0YM.6&+QH:2%^(3B
MQ6Q.VG6A/P4L/VO)V:TZ @$:F>U2?\'],C:2IVU\5Q@14LN+^98E:H/;6Y92
MX$@'?RZ8>$92L4I*^[@19$F(Z_@AB:$Y":9I&,UP 6CG].SJS:[R47.@92YF
M+J+0HQ-D!13M"@JEU .3)C1>R%$#E"IG#*)80LD!50"?F"A29,D-!;H6I.<0
M?[')Q4AC6RU\,^5*07/8ZK##22O&OU'7)IUSL1S]R?('(AWH!Z1::?H6>ECY
M=JH7C,W%)UI-C#88B9:R2((]2S0T#>$9_93R;[%@(J%DP65T23DPY!87E_6/
MM]2/'BUU8ZD?/5KJ7UJ*_9>X"9E/DBVF(QI9KJ 7VX\M\6HEC?VD&%NSP9(-
MU:]WR+*#_16CC:")=O;4RS &M/#YJ3LCSL(]A]B=*.XW9V3JBV' URE9YQ\C
M=MP-\> \K\.XRQQMH@-X%5OHQE454.#81,U1:GQ^D:I*-0\9<G^D*)X'SBWK
M0<<!FZIF^#@>@DUG!B&7-.])C?)]M,^<TQ#T,;@\6C[2F"1+"'J[4C4<Q9O8
M5<KLC;[]=X0^;UV\C%IH;?4+?);K7RIPXNJZG+EI3E!L1R%/X7:%6 $VR.KN
M2MH!NU?1;2G*]IW[8$W;!0L$*2<:IW.^->>8]FI%<SK>1B%QN,]4(N5P0M_/
MFC+5 QF5?$PA]8)DX 80DE(XYDR)ZBRL&+@ASQ20?4\+CCSV+S">\UV9Z6*U
MH]N3=JO9("(.1XC2P(F0U<+3[ H6ET(VRZ[M+S5*.38TU'YX^ZV8C;\\KYI+
M'P.=SJ"0>:8P\+>JQB\S-VC'4ORO2N#S'"A2*9-4%:C"(\VNK<+/7#;7FT@=
MV35N*'LOA]1%9P1R<S"5T9;R[[)+.Y;A%=HIMNPRE5TG66R%E;".+X5[5;_=
M_5'M'';WNR<G@UV^ >?83F2YVB4\:*!V?O*3IQWZ9+=EGO753J=]@K\!+WG6
M4SL]O+-BQ?::$?$T:>]0B(+1>/),"DCVI4E#:QW<2]LYHLWTN_N#@\/->^FT
M>[3N9B/;2*_=6=K(H#U8N1$+^G[-/KIWWH>Q_#*\G-!6>H?[AX>;MD(K[V*5
M50P<FH7S9;4MEB]+[1$_YL88JW=S>%>L8"L'G?V#HZVP<I!15[-!>^O+@PI6
M.MC<:S14RC9&GQX1%%QT#79%^!6/Y[?+L,ZYD>+H>@:EH-<Y8%AU^B>MXO[+
M%EB"6G/2H0H7&_,^C26\'1*8B;@.]WL5(EPBHK:J.C]6T<* ";O;7S.F91"U
MI![\JUNA='K2JW/,?RV8W,[F.WZT^8S-=_QH\ST4W2UK<6>AOUJ#^UI6_IF4
MM9'LO>*%9=]KN]DXY?+186#=B];CG?720PY9X&69(S(85X2C\:-HJAVRIQ;T
M)3KTA#=>E)),.GOWZV[N\=H7X^%&C"RI;ZM170ZE;4U9O,HMKY)9M!?I,:F%
MG)6R8G=E%]_JSS-@C*P)2*LP-??M>E-22L3%IS9Z^.ZAGE:77I(3/983!\>B
MF(HVO5X%.JJJ0*M54/67-=!FHW;1!Y!MW8-M%=!!29'N+BEQQYMV  WIWLIG
MW0X ],/.=EKGH*QU-AL]:&N$AF_7"'Z#?#H&&K;-?X6VU=NC56RA-+50*A$O
M;CS<A2MDHY0(M-L^AHUWL*7!*D9>D4WTV>@K';/.%D;>W5F%VK23@Q^;C9VC
MSG;,HE=E%MTEJPB@N9>MVFQLQ2_JMP&3>W"\!<<88(5E; PJK@-F(8*-KU<[
MV4Z?/WG4YXT^?_*HS_]-S'I3F8T""Y>S/<KZEAJOO/%8CB/!FB=:I3V_.+<#
M=?KV2D(YEU=*^_K&!-XY@A-)M7LK/-![LA!TX-( 9NQ$S23:;\K?EZ+KW+.L
M..#M5!NE/$HG$E7((S=2$[)XEVR3=BJ=N0KU1V2+<;9'XF41_".D]V&[*-5$
MN^7&L#$T>+#S[H]%_O?MZD"O*B&2[U?OF4<>#<LW?6.-1J?X@W,_D D5Q.E8
M;AV-%BW;N*4@31?S<#Y=Q,8Y5_G5YH2X7LP2(!8I"4Y+ H5>&FK4]9[Q9:@T
MLVFQ-@3HLK00>9,.]K5.0F?DN>AN1-9N%N5='\I5GS62VVR40[FO"9!6F\'M
M:6$^]0#-PZ#&7A?VE><UY>J'S;PA Y?$I\E(BK/\'G^!&+')0VVK-P6\+,/3
M&:7YE,1XXC@<>=E5&:*R.%9Z#/-9Q2DAQ)%FB<YHBOX<4S(6Z#]#SVEA@S<>
MTK-,XQ17XRO@9FD%AD7C,2';2YS(BV=/<PALW* J[.]***M^>Z9;=9@FE5#H
M0@!CR)*FYV_E.AQ6IJ/\IPTK"Z.Z;)]5ZVTV3!98SKX1\^4I)_Z"QO0<#&G"
MU<M)8L23[7$I+*R2/07:\KU@Y2J^7?ZVO=>F]AQFI@#.D$(LL=<1TZS69=!9
M#E1ULD#50QA?N".R;IG@2\: A-FUE<UH3*]*!*KWH+Z9S:N^BYW582NW$$3K
MU0;1-CO(EA6CS0L=M+'4[L%^O]<I+[68/5F ;F_)<0>S\.'L\=HEE\.M7X@D
MZLQOSL;YLB2A:BB"3>\O3Q+5I1IJ74$2_W2G0+?SZ!4P7H%NY]$M\/7*^J)Q
M4CS)S0;$-4JL;.-_[1O&617X_;_.W<$G#)]<M5:.90QZ*YBZ9>+EM6U61>["
MP5>N#)$3FO_DOJQ[6?AT5O#'[T]-30KV31'F(-QF8TO*[1G*?;C,K[IEL<[<
M8]G8ZVT;<SM8SO3J/:+><JVB'5H'YX/!EHPKRW2LZB&;J6(-\R*K>HE%U"ZY
MPK^VX+,GU:6NTT>S',P[4/"ZI79[M-;C+>/&;/$M:9X'CT2<B=YZ*#<;QYR.
MU[^_[!UL$2*\J^Q=01(]Y Z>;).+6^\7Z&XT1>YD8*]9:9?!NBT'KE O$F9E
MK8_$V\H=TV7)>\*2]VAKNJUQ$O6MRM/+LYOJG=L/1S.UN^E96W9+W>VPDBQO
M-V(3S]<H;U\+J6QIW'8?C5MKW'8?C=O/E\/Z7L^GD21?X@Q?L//IY2*V]Z>_
MR^36P +E+^5<9:/PI.+6<W/(5C*QH/3UMM%&FHV5=X>6_=+;! 3NG_6(,C\E
M\EF_R0'?C^H=W8_;=]O+65I_K[GVV;,#7A;O2M:46/D.<@56']+(B3G&*A=*
MY;2^^C0FJ>9P.G7^O!0KN4R(IH-X[^=P&L2<H1ZX43C3:N?RYTNB+T[:47KN
M\?<^KKQ&H;\@94CM7+UZ;R@0J3*R J9[3<I2$,ZG'DUN(J;V4JP-G>Z\O'AU
M>;G;;"!3/3L5_#6ZR.]+Z\RA'XZNL4P$!(:AR\G@5ZAY04O1L]#WY1#3'/O<
M<4Q^*:>FQS8=GT[)'UQ^ W>7$:15,\_GG)]9Z')923K!8: +4,.>]+=\P6LC
M\U^FJR)[&J:^S[G\7/"JGMP441(M]]5[H15&_.?'XIY=V_YWA<]_6(F%;Q<1
M][^R(B>NZ%_D:XU'6UVDMII!G6+P<+Z9M4MF2U;\'D?;N6C8=51QT70>U,&X
M<<%=#CUUMHEXVXO#E4S_P0KEZVNAW2TM[=ZCI6TM[=ZCI?UPEO8'3J+;HE#B
M-V)@HV)'7M*_D/F'/$*N9A<DFXO:%%*)'#0CR8N @$?![(4-F08HWR-YBK=>
MS&5PM+N[5 TD*P2R+(:@+ZQ.[6\V#'M%$B<RT[-KI<Q[(?1-J3W)E=RDPE^6
MRQ,:MVM>+CX;GJOSP1R1-EBQ1A)>!49/U+/SYR,G(AB.]F^<>(1Z]/1P__SY
M;!'R#ZR&HM1=_I>\B'\_Q?>!CFY0KUDL%?.U1F59>1T@GT\=<[%UMM"^%-:0
M&C[\M\ +/SHQK35@<T>LJ?WLF:,FD7,#ZRD7*_J3,]+14%0B,O%3S_<=X@XO
MG"CZ27-:\--LJ);"4K7"?848:T%?0Z$C^!_22')J>5-A 13IC3;*>R3_RRTP
M&%OR&J[F^L[,%J:7RQJXE0';@*F0QY3BMRCS0,0?.+Z,3MJ>%"EDH) N;FMZ
MVML-7-(IUE$Z4\YLX4.KQ )\;XY_<L7"V%36E>6Y*6GS08:?60ITA?&U]C4H
MQM2B"J"5$C2D>&6&=$Z+V)^3H6K_(*,WFCI#-Z0';+X*  I)UC'XN^_H@KP7
M_\W8\?PT0NG%*)F:U<G0CC\AA$93G7**N,,KM;G-9C6<J.%$3B&'F1@1X89!
MOR.-,=FEL2]8W#7?P3!:( )!*OP,6=W.G,!6?(!74&$X'/%[TJ-S2NJXAR<A
MV^AOWKXADLI+;15PS&VBI%-"3ES9YVA3#EL_\?[DBI08W#$843O_\:[3T=0K
M/\9$3C0*)5ABE2XZMS3TD)<TYU,Q3R/Z/]H :P)H5H]*I'DK4(+[[Z:,XS=M
M'SBN*W?^8<E.MREQ9NKG.L/P!DU@''2MR=/*33>)O"9GE<'77=JR]5"2OR"O
M0$E9-4]FUU*^FWE[F"8C)JVBNFTD5[%&RY(0XX*<8T^[3U8QZ)SUJ9SS-1L[
MG%"[%1NFUT)< "CX:)]FXB0L"Q-N+LQ3$+3TC"04^!")J2CC4D6&._0A,"+#
M?/2<#'!?&_811D,/L,FXD\I^W)+)FNO&,NL&5D)\4@J4WYC%V*/HQ%FR;LEE
M)S6VZ&&T2#"JFJ4^43*9[=KD:L0ZP,)OX"7()6E+T( ?(4/ ^DAZ,2^8TQ.:
MK[98TM=R>K>TD/J/%I*UD/J/%M*7EAN7K V+QG;^[O3"Z,Y0TN <K5P:BS3S
M#U)1$V<TQ:6D-A%O)/57)G(1E9BPN2WFS=#1K'K';4BRP VX/FBF"K;5^5@9
ME5*>Q+7215C3YAK0J'EBRX6J7\-)LO>?<($;7-[>&U*>7.>GP'7BZ5/?NRYJ
M*W(S,2MV$PYCZ,9NR?"IO64@\I%;0W*[)_B6307/I?+7*XJUQA#;),[2D6;A
M:1MT9EY70!6 (*WUF[FR^X+TEG&*;>U=D+(,9'Y?/0[6Q<U-T7W/0B@R$"I4
M@'^9N^$S-V9AK)+!SK0G0^X8SR,W(/2]L=XCI1IMU+CUB?EUL+MVZG-;JYCO
M%.-N)5,MQTN(;.VGRVO@\(J9HRLM$$V@Q3[M;9IY.U<X7\5WU&%G;T8 2G)(
MMM8,7ZDJ.#!^YR57.2_#(8"R,:9%5\8WPD,J"X3CO<9)LF)]W%-9]3M[ZKX+
M[W'"P_%^__!8'.$F%:Q#3TZJ):I@MHG=ZR_:ZM18$5#66R!3)!7D W49) <\
MCEHY#.EZG^ ?T=S^9MGPD*;2S<;@6$U#,/LBQ7!)9%^J)W!3 )?VNF@5..%2
MMP>Y"XQ E:G)D-5Z#'#QW.%F66LR[>Y2,F=;#!P(P >=HV7">7-65^;T7N5F
MMUL.XB>#_<')\E(NUB_E+D&1[99R('DJQ_L'@QK(H#&J>K./UJ=J=G9Q5J@R
M]Y=2:[9;VX#/S<%^MUN!%.[_JW<?WVU?G%9M7YMVN[5QXGK_:+_?Z91/\+>C
M#)RAOYIIS,(\X=0G^U,'FK2E-VR.SD./TV@OT67F#,WPKC(_CR,9==^!UB!=
MHG*/:ZQ9!9?^=!G\,NUZE>.>!&0.WVD)OMS%AYL-)F7XJITWEV=7N[9S2V@Z
M\-#?6;,>:RPL-^#)<971>FG)-I-(BU= *EB063%.]B!!TGAO2NKRGFV5M_/O
M7]^\1,H0OX<_R*281B%\-/*7K15THX-PCV#ATT&[T5FOO9U?/[RTW1-%]<9)
M2]@9L6 ;0F0A;4W\NWEU2NCVV/%8#R,T.,H3G4Q5"HZNF%9#/*PM5"G:W2X7
M88]U!6<P' 1G9$K-I7ET B,DD$XZ1G$8ZN06%DH5Q.*$+AP:PM4_WT,R>/20
M6 _)X-%#\L69K52.R1CHB QP= !%+%'?Y-'39"-SX[[JYCCKK&E4H<H8+"C;
MWED8'KL!8AE^51,M<_1--X8PY\G<*6T3+_B'J@JO9L-H$>Z]YNC=55;7]#L0
M_B\<TZ#<2U!5:S1U KXF-E;.*.MH-_8X_RY68Z(R>N(AV39.4L3+6W6N@MSM
M,&:03IUH)K7K2M7JB+P<U&&:!(C?W&)?TDU$*DD5@T6H= ?_&GJTAW F3E@Y
MB++&?E.-W$ (6=-;SHM<V-$$)!3]9_U;9AJQ77KC<2&S?&X=F#B^FH>)EHY]
M[#;C5=(^TCC[;DSJC2_>R4C3T2-ASY'>[$L.,V/_LA/\QIU_G)&6?DS5?H2K
MSB&#/\Q[&*D#:6$4FU.)]2+RRK;MMW,@SVW=0?4NC!)D-J J%<FNHN_G'0(_
M<U*7WBVT#YN<*<Q:X5X,[X.ELBND1[CAC#BC.@T<XF.I!/E?ZD\D%I.I@_95
MW\61)]N3A M@\2>D2B4^N^QALU">"91;<M:R^'#>PI(!G10 [5A STE5)AVT
M &DX>&A@,4:S*I.HC"G8AGI?:(B\?DFF:*?#J3V06/79/8O:*,#V2R:*0F,M
MLG?"&2T,M$6J.82ME)S/.WM5@/KMG,NW)!6^'\OX:LI-?KEUFW+)3%:A))%+
M[<!1L7]K;C41D4U36@5\T]<M-K-R@2;?0X6.DS&.W]3S72Z*6'D-'RLK6M %
MZX46B;HDI#@-S=CLR\Y16DTV&Q$FIHMT@.)5+,E$\(&L(5;-B]Q(J"*?K""Z
MH_SY6E3T+8W#@T?CT!J'!X_&X4-1'IJRR_G<LO?Z/Y=EEGIR=?I'K36LJ>0K
M+R=<U=S?W0G^U3L\WFU7JG!O&+97SN-:[M\%<V,6$@/+ZG$7QL?]73N!7"/,
M9BGTKE$T"7%/I(T=K)].\I,YTY,S'^:.%TB)#M)((DF<S)4A)YX[I XA!NK0
M^R'[!,8Z<M"O3,Q_^ZJDJG+,HP#^P\-MP=\_W+!P0+]SN-O.VP9N!?[N7P)_
M[?@6\'SYZ"?B+QM0+#"?(+%T;^*G"3)\"Y#,@(B+,[:6D&ULA&>V1481KLMD
M7<@R5#M'@Q]E^5*O;#E34CL<6D2GOI5AR)W!D8S2Q?TC<<8@=Y6^XQ!FC"Y!
M\D;_L%+2LH_WZX"W<]233P[X&I;OY^@J%:7G(L LW T061W.;/$9Z*'?[>\J
M=DYQDG-8?+WP"I',,I)W@#A<HUJON:Q9@!CYQ0FK06/&>X[);O]'<9KUI*:I
M[0*$VUPF&)TUY9@O(OT)N8;Y;YTE,NCUC[<]7JBTLY&[#0YZ!>ZV H'5KDN9
M KIGHR5Y7T@[Y,HS)O!8=\A4Z8RMFJD,Z3K.)*$$R:VO@/&X>]B"ZV8K-M4I
MGW7T0$1S382A>!%U(:,ZHV\.J@W2V9X;ID-?)Z2'ZYG-I""*O5Q'E3]-$@ D
MZY-F6S[*UF^(MZ.;6%N1(B59QNLWM>X6##.Y.ZZ^0J6]K67PP?$2=-&ZE FH
MV:@YP+VUYY<1DL&FE1'(?M:"K=2F,^NR0\]3GQZCJ8">#>GE>)85VP5 2N7P
M ?)BO<FV>KT%S-$UK;C7IW*!)\<I"@^( [+8T'-GD'V!9DJE&SP2-[SVW$"#
M>?Z>1K2Z>!J.KEOEJNTM\5_L2>J>D@L&^3V.K/Z(>53!Y\G;T[7"IX30HR6$
M]@^.:SG"CA#U??#9LF%+ON*31)*]W<JOAM0!IGIE1C0A=Q'3!$Z%,@0D\=R+
MY/I/!I@5F"Z7N#Y22+DOI!89_B1XKO9_L<NMW*Z)]3Q>HMB,XTG+&"+":\<W
M>Z8YT!.!X^)\%2;ALA1&IL4Z24QN4>4"BE/5-;I'TM;V8'M5>I4NEWGJ(1FZ
M]72P>HIZD;!![2J02W:HFXW\5.<(%XE+__!UBKL+>FRSU+:CA3+4 *U-O/<I
MNV;J#WW6N9(TIMK;UO '(KD9+S\[?RY-XD=TH@G)OWM1>*-'GB<7(RP(=NL8
M&[&4/"G):!^^1_Q^5+K51YJ(7495#3D:]+=F\(/U.*.5Y%K6@U+'$C%8=.=,
MI(AF+*1*!AFIU/*3E6E/JU@-JWE+Z*CPE%6,=6!NN.0;+#&5,L7R<FF+4;+,
M3[@R20'/5>'='62XK;E<6D;NR88#6=2@(=H'1_?D *LLKY(:6#S2!;R7)'ZI
M$U M6G.DK^@N)%<MZV!W\NIB:XYYO %TU=K_+$E[G0+\FHT'.B3+!Z(*MCKM
M"-Y:/$&$,0%^#/O*]2/K8+ 4GM_?@@TZ#B.G1MVV]75+294%-ML[6 /BLA@>
M'&WV, PZAP\KE !1W$2LH:S5<J;$E0SX=#1R_)' [WQEV_EUECZWFB_G&9<[
M6K#?(4M0CI6;LE&]P2 :+&EXZ"_?5BL-F#)6>F5=X:\!O[N>YU=9=,Y<"[PB
MZ\T;%4_"%CJ!$T_;ZA7N:A<L*A?)<IRTP+$3<X$3 ;\@2]N;1^&$- J,^P2>
M$\EQ6)%D3A:H<H$=$X7AT(<A8""OI7HR0*Y ' .+)^6H":?RZ"2G?MG$H5EK
M.=$'N1B5Q)LR#78'W:TYW28A 0+JUY["=3;Z7]4-,S9?H]J5']8S.!&GU:-Y
MM(X[W4DQ8K <=;X(6$JL7!4V:G6&_%S$,WCP+"?'59EAG$1I 3 @&IP<%K,(
M2--W/MKC:=P,-DQ_"6Z#K=W&G2U,C?Y!]TY<_>Y@<^)54&LW&UNY ^[E#,@+
M=A;/8@\#XN)!X=[!.L]?,:<?_JSNR>[6I_GH_MP;*]FLC1AVO)_3G#68!2:M
MI6!&O;"U[%TJDDP7;DYYS49!H1ATMCZRFSA9!:Z#DW52<5FW'=0)LV6KQ3HY
M<H?GZ>75*G55.?'(2Q!ETS$7QZ##J&Z<R!NAP(R>A30H/:Q$A#B/W0P^],.0
M_NOY7I0.,S,F)TJFQM.$3P%$[=:F87^3"LP!H)/=M;[131154^6G*@D*@!E[
M<9+Z#%MD\,$W2$_]% $0D=U&_S=H$?+/RT3\5=_KD]43<P'#'.HH\BZ]:7)7
M\ Z'#)AK\Q4(. *SNK_+N\Q^JE97*-!%]DZ=&T%^$H#$J>N2&N1JAXZ _%)A
M4P='6[N3^OW-E''01YSA=+5?\EZD06R]1-JG!J79H#2"=<'R61L[T7(EXQ""
MT4Q4-T\%,H>#DZU94&43FX,/)E&MZ*X'^(Z.Z\,T]]8L[K<2/HLV?('0YU&%
MI/MM$VCDYJ/VSRQ8UD.EQ();=*<G(]A;+07O,'X[S.BU)%5[$G'=2FP?XO5.
MT0]SYTA0$0++'L&5SO\5FRJ^@7-\K2L/EXYW[GC.'S8;LW24%5\I,)!6Q9ZR
MJN'2J$-?:Y<O&LVXRRVJBZD;LG*T;SW.F?^)>%JL(<*%GDAVV-(RN+3D3%+?
M65'NZ"M*L=DFN>OP,;G+)G<=/B9W/5S&U5DXHR/Y/>9V)59DC00$2Z:<A(G!
MH7,%N\B135(7RWHN>[O3Z];DVQQNGBJNF4M5I^H<[JJ;6+D.Z0Q#YT^VF?GY
MP:Y(#5(P/&1_[\!10F_V.26D+H) XJ_'K_18)3.+/^9'W5Z62!*189JD$&O]
M[*>:="+)$B[N+]_-73-C;&I.>4.'O;)L/ACDRS[@WCP!7&0. 432EC*Q/F ]
M-M_)!IC0;P4=@DMUN3I+:9O/=8*+J#N]$TG"22> &^L)MF$\_2VZ@7$+T=^\
MHI0^CI:]0<5@74^Z#*$6HM0_9'JJ9LMQ^A=2ZK@ZT4YO63_F%*\D\^W?&2>K
M\7!PDL-=(%L/R4$%7WT!B2")_NP4P7=<QI" <QMP]5:BIU?!B,F9"H@_S(T&
M:6%;"^V<!GHK4J?N=:(]>\%GSVIXA9H.)N,)Y\R;DXT\2V?.<$5BU#)BCOB
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M,D_)-\EQ;'PSB]_Y]2XE9Z478C_]KVB.XG\.VR;R<FLTW%33+/\ 4$L#!!0
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M+GAS9%!+ 0(4 Q0    ( +PY;E0OXJI@_PH  &R'   5              "
M 8%:  !N:W1R+3(P,C(P,S$T7VQA8BYX;6Q02P$"% ,4    " "\.6Y4;:R"
MI%,'  "]6   %0              @ &S90  ;FMT<BTR,#(R,#,Q-%]P<F4N
9>&UL4$L%!@     %  4 6P$  #EM      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
